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ABSTRACT 
 
Overt hypothyroidism frequently leads to liver dysfunction. Subclinical hypothyroidism (SCH) is 
linked to abnormalities of lipoprotein metabolism, however, data on liver function are lacking. 
We analyzed the effects of L-thyroxine (L-T4) therapy on liver function and their association 
with changes of serum lipoproteins in SCH as part of a prospective, double-blind study. 66 
women with SCH were randomly assigned to receive either L-thyroxine or placebo for 48 weeks. 
Circulating liver and biliary enzymes as well as serum lipid levels were assessed at baseline and 
after 24 and 48 weeks. Alkaline phosphatase as parameter of hepato-biliary function increased 
after 48 weeks of L-T4 treatment (p=0.004). Circulating levels of alanine amino transferase 
(ALT) and serum aspartate transferase (AST) did not change during L-T4 treatment. However, 
there was a correlation between both, ∆AST and ∆ALT with ∆-total cholesterol (r=0.60, p<0.001 
and r=0.52, p=0.002, respectively). Similarly, both, ∆AST and ∆ALT, correlated with ∆LDL 
cholesterol (LDL-C), respectively. Consecutively, patients with marked decrease of serum lipids 
during L-T4 therapy had a significantly higher decrease in AST and ALT, respectively, as 
compared to patients without amelioration of the lipid profile. Thyroid hormone replacement in 
SCH affects biliary tract function, yet, has no overall effect on hepatocellular enzymes. The 
relatively strong correlation between changes of serum AST and ALT with changes of LDL-C 
levels suggests that the mechanism of decreased LDL-C observed in restoration of euthyroidism 
in patients with SCH might be caused in part by changes of hepatic lipoprotein catabolism and a 
restored hepato-cellular function. 
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INTRODUCTION 
 
Normal circulating levels of thyroid hormones 
are required for both, normal hepatic function 
and normal bilirubin metabolism (Fagiuoli et 
al., 1993). Hence, overt thyroid dysfunctions 
are frequently associated with abnormalities of 
biochemical liver tests and in severe forms 
with histologically evident hepatocellular 
damage (Muller et al., 1994; Klion et al., 
1971). In addition, bile flow and biliary output 
of bilirubin and bile salts are reduced in severe 
thyroid failure (Van Steenbergen et al., 1989). 
In patients with overt hypothyroidism (OH), 
L-thyroxine (L-T4) treatment reduces elevated 
serum total and low density lipoprotein 
cholesterol (LDL-C) concentrations as well as 
circulating apolipoprotein A, B and E 
concentrations (O'Brien et al., 1997). The 
mechanisms accounting for these changes of 
serum lipid concentrations are complex. In OH 
alterations of hepatic function might play an 
important role since, for example, the activity 
of hepatic lipase is decreased (Tan et al., 1998; 
Packard et al., 1993). 
Subclinical hypothyroidism (SCH) is 
characterized by the finding of elevated TSH 
levels in the presence of normal circulating 
thyroid hormones (Cooper, 2001). A 
significant decrease of total and LDL-C after 
physiological L-T4 therapy in SCH has been 
shown by our group and others (Meier et al., 
2001; Danese et al., 2000). However, the 
mechanisms accounting for these changes 
have not been investigated and there are no 
data on liver function tests in SCH. Therefore, 
the aim of our study was to investigate the 
effect of L-T4 replacement on circulating 
levels of hepatic and biliary function using a 
double-blind placebo-controlled study design 
and to investigate a possible correlation 
between changes of liver function and changes 
of serum lipoproteins.  
 
MATERIALS AND METHODS 
Study Subjects and Design 
 
The present analysis was part of a prospective, 
double blind, placebo-controlled study, whose 
design and patient characteristics have been 
described previously (Meier et al., 2001). 
Briefly, between September 1993 and May 
1997, 66 women with SCH were enrolled in 
the study. All patients were examined and 
followed-up in the Thyroid Research Unit of 
the Division of Endocrinology, Department of 
Medicine, University Hospital Basel, 
Switzerland. Patients aged  18 to 75 years, 
who had TSH levels higher than 5.0 mIU/L on 
two consecutive blood measurements, an 
exaggerated TSH response after TRH 
stimulation, free T4 concentration within the 
normal range, and were in good general health 
were included.  
A total of 63 women (mean age 58.5 ± 1.3 yrs) 
completed the study according to the study 
protocol, with no serious adverse events 
reported. The underlying thyroid disorders 
leading to SCH consisted of autoimmune 
thyroiditis (n=32), Graves’ disease (n=21; 
previously treated with radioiodine, surgery or 
carbimazole), toxic multinodular goiter (n=1, 
previously treated with radioiodine), surgically 
resected goiter (n=6) and idiopathic SCH 
(n=3). The frequencies of underlying thyroid 
disorders were equally distributed in the L-
thyroxine and placebo groups. Lipid lowering 
agents were stopped at least 6 months before 
enrollment to the study.  
Alcohol intake, assessed as daily intake of 
wine, beer and other spirits (glasses/d) was not 
significantly different between both groups.  
During the course of the study the use of other 
medications was registered. In summary, the 
following over the counter and prescribed 
drugs were taken: non-steroidal anti-
inflammatory drugs (L-T4-Group: 5/31, 
Placebo-Group: 3/32), benzodiazepines (T4-
Group: 4/31, Placebo: 3/32), barbiturates (T4-
group: 0/31, Placebo-group: 1/32), diuretics 
(T4-group: 1/31, Placebo: 1/32), β-blockers 
(T4-group: 3/31, Placebo 3/32), 
bisphosphonates (T4-group 0/31, Placebo 
2/32), magnesium (T4-group 2/31, Placebo 
0/32), haloperidol (T4-group: 1/31, Placebo 
0/32), nitroglycerin (T4-group: 1/31, Placebo 
0/32) calcium antagonists (T4-group: 1/31, 
Placebo 0/32) and ACE-Inhibitors (T4-group: 
2/31, Placebo 1/32 ). The intake of none of 
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these drugs was different in the T-4 treated 
group as compared to the placebo group. 
Assay methods 
Serum samples were collected in the fasting 
state, immediately put on ice and processed 
within 30 min. They were kept frozen at -70°C 
until assayed. Laboratory analyses were 
performed at the Department of Central 
Laboratories at the University Hospital Basel. 
Serum concentrations of hormones, lipids and 
liver enzymes were assessed at baseline and 
after 24 and 48 weeks. Serum TSH 
concentration (reference range, 0.3-4.0mU/L) 
was measured with an immunometric assay 
(Delfia, Wallac, Inc., Turku, Finland). Free T4 
(8.0-23.0 pmol/L) and total T3 (1.2-3.1 
nmol/L) were determined by microparticle 
enzyme immunoassays (IMx, Abbott 
Laboratories, Inc., Chicago, IL). Alanine 
amino transferase (ALT, reference range 10-37 
U/L), serum aspartate transferase (AST, 11-36 
U/L), gamma- glutamyl transpeptidase 
(gamma-GT, 8-66 U/L), total alkaline 
phosphatase (ALP, 31-108 U/L), bilirubin (5-
26 µmol/L), globulin (18-34 g/L) and albumin 
(38-52 g/L) were measured by Hitachi 917 
(Roche, Rotkreuz, Switzerland). Bone alkaline 
phosphatase (B-ALP, 8.0-16.6 µg/L) was 
determined using an immunometric assay 
(Tandem-MP Ostase, Beckman Coulter, 
Fullerton, USA). 
Total cholesterol (reference range 3.0-
5.2mmol/L) and high density lipoprotein 
cholesterol (HDL-C, 0.9-2.2 mmol/L) were 
assayed enzymatically by automated 
procedures (Roche, Rotkreuz, Switzerland). 
LDL-C levels (1.6-3.4mmol/L) were 
calculated using the formula of Friedewald. 
Apolipoprotein AI (0.95-2.0g/L) was 
measured using immunonephelometry 
(Beckman instruments, Inc./Hybritech, Palo 
Alto CA). For the original study, thyroid 
hormones and lipid values were both measured 
in duplicate at each time point within two 
weeks (Meier et al., 2001). In contrast, other 
parameters, e.g. liver function tests, were only 
measured once, at the first visit. For our 
analyses shown in this paper we therefore 
included only data of thyroid hormones and 
lipids of the first visit. The study was approved 
by the local ethical committee. All patients 
gave their written informed consent to 
participate in the trial. 
 
Statistical analyses 
All data are expressed as means ± standard 
deviation (SD) in text and tables and as means 
± standard error of the mean (SEM) in figures. 
Unpaired t-test (two-sided) or Mann-Whitney 
U test in case of nonparametric distribution 
was used to show differences between both 
groups, as appropriate. We calculated delta 
(∆)-values of all parameters by subtracting 
pretreatment values from posttreatment values. 
Treatment effects in the L-thyroxine or 
placebo group were analyzed by paired 
Student’s t-test or by Wilcoxon signed rank 
test, respectively. Two-tailed P values <0.05 
were considered statistically significant. Data 
were analyzed using Statistica for Windows 
(version 5.0, StatSoft, Inc., Tulsa, OK) and 
were analyzed by intention to treat. 
 
RESULTS 
Baseline characteristics 
At baseline the two groups of women with 
SCH (L-T4, n=31; placebo, n=32) were 
similar with respect to age, body mass index, 
alcohol consumption as well as medication 
intake. In both groups, basal TSH levels were 
elevated with an exaggerated TSH response of 
more than 35 mU/L after TRH administration. 
Peripheral thyroid hormone concentrations 
(fT4 and T3) were within the lower reference 
range. The patient groups were also well-
balanced regarding baseline circulating liver 
enzymes, bilirubin, albumin and globulin as 
well as serum lipid levels (Table 1). 
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Table 1. Baseline characteristics of the subjects  
Characteristics L-thyroxine group 
(n=31) 
Placebo group  
(n=32) 
Age (yrs) 
BMI (kg/m2) 
Alcohol (glasses/d) 
57.3 ± 9.6 
24.5 ± 3.0 
0.3 ± 0.5 
57.0 ± 10.9 
26.1±4.1 
0.2 ± 0.4 
Thyrotropin (0.3-4 mIU/L) 
Free thyroxine (8.0-23.0 pmol/L) 
Triiodothyronine (1.2-3.1 nmol/l) 
14.1 ± 9.8 
11.8 ± 1.6 
2.0 ± 0.5 
11.4 ± 5.8 
12.2 ± 1.4 
1.9 ± 0.3 
Gamma-GT (8-66 U/L) 
Total ALP (31-108 U/L) 
Bone specific ALP (8.0-16.6 µg/L) 
Bilirubin (5-26 µmol/L) 
Albumin (38-52 g/L) 
Globulin (18-34 g/L) 
AST (11-36 U/L) 
ALT (10-37 U/L) 
17.6 ± 10.4 
63.3 ± 20.8 
9.6 ± 4.1 
10.5 ± 4.0 
42.7 ± 3.7 
29.7 ± 4.6 
19.8 ± 7.3 
18.2 ± 9.4 
20.8 ± 15.7 
69.7 ± 28.1 
10.2 ± 4.8 
12.5 ± 7.9 
42.8 ± 4.0 
30.5 ± 5.2 
19.4 ± 5.5 
21.3 ± 15.1 
Total cholesterol (3.0-5.2 mmol/L) 
LDL-C (1.6-3.4 mmol/L) 
HDL-C (0.9-2.2 mmol/L) 
Triglycerides (0.5-2.3 mmol/L) 
Apolipoprotein B-100 (0.65-1.35 g/L) 
6.3 ± 0.9 
4.0 ± 1.0 
1.7 ± 0.4 
1.3±0.5 
1.3 ± 0.6 
6.1 ± 1.3 
3.8 ± 1.3 
1.6 ± 0.4 
1.5 ± 0.9 
1.2 ± 0.3 
 
Statistical significance was assessed by unpaired t-test (two-sided) or by Mann-Whitney 
U test in nonparametrically distributed data. All characteristics at baseline were similar 
between both treatment groups. 
 
Effect of treatment on thyroid hormone 
concentrations 
 
In L-T4-treated patients, TSH concentration 
decreased and remained within the reference 
range at least for the last 24 weeks. Mean 
serum TSH level at the end of the study was 
3.1 ± 1.6 mU/L. No patient had a blunted or 
absent TSH response to thyrotropin- 
 
 
 
 
 
releasing hormone, thereby excluding over-
treatment. Peripheral thyroid hormone 
concentrations (fT4 and T3) remained 
within the reference range. As expected, no 
change in any variable of thyroid function 
could be seen in patients treated with 
placebo (Table 2).  
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Table 2. Parameters before and 48 weeks after treatment with L-T4 or placebo  
 
 Treatment with L-thyroxine (n=31) Treatment with Placebo (n=32)
Variable Before 
treatment  
After 48 
weeks 
p Before 
treatment 
After 48 
weeks 
p 
Thyrotropin (0.3-4 mIU/L) 
Free thyroxine (8.0-23.0 pmol/L) 
Triiodothyronine (1.2-3.1 nmol/l) 
14.1 ± 9.8 
11.8 ± 1.6 
2.0 ± 0.5 
3.1± 1.6 
18.2 ± 3.4 
1.7 ± 0.1 
<0.001 
<0.001 
<0.001 
11.4 ± 5.8 
12.2 ± 1.4 
1.9 ± 0.3 
9.9 ± 3.3 
12.5 ± 2.5 
1.9 ± 0.1 
ns 
ns 
ns 
Gamma-GT (8-66 U/L) 
Total ALP (31-108 U/L) 
Bone specific ALP (8.0-16.6 µg/L) 
Bilirubin (5-26 µmol/L) 
Albumin (38-52 g/L) 
Globulin (18-34 g/L) 
AST (11-36 U/L) 
ALT (10-37 U/L) 
17.6 ± 10.4 
63.3 ± 20.8 
9.6 ± 4.1 
10.5 ± 4.0 
42.7 ± 3.7 
29.7 ± 4.6 
19.8 ± 7.3 
18.2 ± 9.4 
19.8 ±16.1 
68.0 ± 25.6 
10.2 ± 4.5 
11.5 ±5.1 
40.6 ± 4.6 
32.6 ± 5.4 
20.4 ± 5.1 
18.3 ± 7.8 
ns 
0.004 
ns 
ns 
0.04 
0.01 
ns 
ns 
20.8 ± 15.7 
69.7 ± 28.1 
10.2 ± 4.8 
 12.5 ± 7.9 
42.8 ± 4.0 
30.5 ± 5.2 
19.4 ± 5.5 
  21.3 ± 15.1 
17.6 ± 10.3 
68.0 ± 28.3 
9.8 ± 4.7 
11.9 ± 6.1 
41.7 ± 4.3 
32.5 ± 5.1 
19.8 ± 6.4 
18.5 ± 11.2 
0.03
ns 
ns 
ns 
ns 
ns 
ns 
ns 
Total cholesterol (3.0-5.2 mmol/L) 
LDL-C (1.6-3.4 mmol/L) 
HDL-C (0.9-2.2 mmol/L) 
Triglycerides (0.5-2.3 mmol/L) 
Apolipoprotein B-100(0.65-1.35 
6.3 ± 0.9 
4.0 ± 1.0 
1.7 ± 0.4 
1.3 ± 0.6 
1.3 ± 0.3 
6.1 ± 1.1 
3.7 ± 0.9 
1.7 ± 0.4 
1.3 ± 0.5 
1.2 ± 0.3 
0.02 
0.004 
ns 
ns 
0.04 
6.1 ± 1.3 
3.8 ± 1.3 
1.6 ± 0.4 
1.5 ± 0.9 
1.2 ± 0.3 
6.0 ± 1.1 
3.7 ± 0.9 
1.6 ± 0.4 
1.5 ± 0.9 
1.2 ± 0.3 
ns 
ns 
ns 
ns 
ns 
 
Significance was determined by paired t test (two-sided) or by Wilcoxon matched pair 
test in case of nonparametric distribution. 
 
Effect of treatment on serum lipid 
concentrations and liver function 
 
After 48 weeks of L-T4 treatment, total 
cholesterol, LDL-C and Apolipoprotein B-
100 levels were significantly reduced, 
whereas HDL-C, triglycerides and 
apolipoprotein AI levels as well as 
lipoprotein(a) remained unchanged (Table 
2). 
Total ALP levels increased after 24 and 48 
weeks, respectively (p = 0.05 and 0.004). B-
ALP did not alter significantly after 48 
weeks of treatment. Gamma-GT tended to 
increase after 24 weeks of L-T4 treatment 
(p=0.06), however, remained unchanged 
after 48 weeks. After 48 weeks, circulating 
globulin levels increased (p=0.01), whereas 
serum albumin concentrations decreased 
significantly (p=0.04). Serum bilirubin 
levels were transiently increased after 24 
weeks (p=0.04) without a significant 
treatment effect after 48 weeks. In the 
placebo group, there was no treatment 
effect, with the exception of a significant 
decrease of gamma-GT after 48 weeks 
(Table 2).  
There was no overall significant treatment 
effect on the hepatic enzymes AST and ALT 
in the L-T4-treated group. However, there 
was a positive correlation between the 
changes of circulating total cholesterol (∆-
total-cholesterol) and ∆-LDL-C and both the 
∆-AST levels (r=0.60, p<0.001 and r=0.52, 
p=0.002, respectively) (Figure 1) as well as 
the ∆-ALT level (r=0.51, p=0.004 and 
r=0.38, p=0.03).  
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Figure 1 Correlations between the changes of circulating total cholesterol (delta (∆) 
cholesterol) and LDL-cholesterol (delta (∆) LDL-cholesterol), respectively and ∆-
aspartate transferase (∆-AST) in the L-T4 group. 
 
Similarly, we found a significant correlation 
between ∆-Apolipoprotein B and ∆-AST 
(r=0.35, p=0.05) and ∆-ALT (r=0.47, 
p=0.007). In contrast, there was no 
significant correlation between these 
parameters in the placebo group. 
Consequently, in the patients group with 
best treatment effect on L-T4 therapy (∆-
total cholesterol levels above the median 
and ∆-LDL-C above the median, i.e. 
"responders"), ∆-AST levels were 
significantly higher than in the group with 
∆-total cholesterol and ∆-LDL-C levels 
below the median (i.e. "non-responders") 
(Figure 2). Correlations for ∆-cholesterol 
levels with ∆-ALT levels showed similar 
results.  
In contrast, correlations between ∆-lipid 
levels and the ∆-values of biliary parameters 
gamma-GT, ALP and bilirubin were not 
significant. Similarly, we found no influence 
of alcohol intake, menopausal state, intake 
of drugs other than L-T4 or placebo, 
respectively, or body mass index on 
different parameters of liver function.  
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Figure 2 Comparison of changes of liver enzymes (∆-AST) in patients with good 
treatment effect on L-T4 (∆-total cholesterol levels and ∆-LDL-cholesterol levels, 
respectively, above the median, e.g. responders) and in patients without treatment 
effect on L-T4 (∆-total cholesterol levels and ∆-LDL-cholesterol levels, respectively, 
below the median, e.g. non-responders). Diamonds represent means, boxes SEM and 
whiskers 1.96. SEM of the combined data. 
 
 
 
 
DISCUSSION 
 
The principal finding of this study is that in 
female patients with SCH restoration of 
euthyroidism resulted in a significant increase 
of total ALP levels, whereas we found no 
significant changes of hepato-cellular enzymes 
(i.e. AST, ALT). However, the correlation of 
changes of hepatocellular enzymes with 
improvements in LDL-C was relatively strong. 
According to the literature, thyroid function 
affects bile flow and composition: bilirubin 
excretion decreases in hypothyroid and 
increases in hyperthyroid rats (Gartner et al., 
1972; Layden et al., 1976). In addition, 
gamma-GT levels are decreased in OH (Azizi, 
1982). Mechanisms accounting for these 
changes in experimental hypothyroidism are a 
decreased biliary function, i.e., of enzyme 
activity, bile flow  and output of bilirubins and 
salts (Van Steenbergen et al., 1989). Our 
findings suggest a slightly decreased excretion 
of bilirubin and ALP into the bile in SCH, 
resulting in transiently higher serum levels.  
Some publications evaluating patients with 
OH found elevated concentrations of AST and 
ALT (Fagiuoli et al., 1993; Gow et al., 1989; 
Tajiri et al., 1984; Burnett et al., 1994) with 
normalization after adequate thyroid hormone 
replacement therapy. However, these studies 
were uncontrolled, and the number of patients 
was small. Serum AST and ALT are markers 
of hepato-cellular function. Increases in 
circulating liver enzymes may either be due to 
their increased synthesis and secretion, or to 
diminished catabolism. Since hypothyroidism 
is associated with a decreased metabolic rate, 
the observed decreases of hepatic enzymes 
during T4 replacement during those studies 
might rather be due to increases in catabolism. 
In addition, elevated AST and ALT levels in 
OH may also be caused by increased 
extracellular leakage of injured hepatocytes. 
Accordingly, hepato-cellular damages 
(reflected by elevated AST and ALT) caused 
by alcohol, drugs or viruses is typically 
accompanied by hypercholesterolemia 
(Vergani et al., 1978). Hypothyroidism can 
manifest itself with elevated serum 
concentrations of hepatocellular enzymes and 
is also characterized by dyslipidemia, 
suggesting an underlying unifying mechanism 
-8
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for both changes. Interestingly, we observed a 
highly significant correlation between changes 
of hepatocellular enzymes (i.e. AST, ALT) 
and improvements in LDL-C. Accordingly, 
patients with the best treatment response of 
LDL-C on L-T4 therapy (i.e. a maximal 
lowering of total cholesterol and LDL-C levels 
based on median values), demonstrated a 
significantly higher decrease of liver enzyme 
levels than patients without a significant 
decrease in cholesterol in response to L-
thyroxine. This finding is noteworthy, 
however, a causal relationship cannot be 
drawn from a correlation analysis alone. 
Pretreatment values were not predictive for 
these changes.  
Thyroid hormone replacement in 
hypothyroidism has been observed to result in 
increased LDL-clearance, presumably due to 
increased LDL-receptor activity in the liver, 
which has been reported both in vitro (Salter et 
al., 1991) and in vivo (Thompson et al., 1978). 
In addition, restoration of euthyroidism 
increases the activity of hepatic lipase, which 
enhances the conversion of intermediate 
density lipoprotein cholesterol (IDL-C) to 
LDL-C and influences LDL composition. 
Restoration of euthyroidism improves LDL-C 
disappearance further which contributes to 
hepatic lipase activity as well as LDL receptor 
activities (Packard et al., 1993).  We speculate 
that the elevated LDL-C and total cholesterol 
concentrations in SCH could result mainly 
from a decreased synthesis of the hepatic 
LDL- receptor. Conversely, the observed 
association of beneficial changes of 
lipoproteins with decreased serum 
concentrations of liver enzymes is probably 
due to a general increase in catabolic activity 
of the liver during L-T4 therapy or possibly 
due to a diminished leakage of intracellular 
hepatic enzymes upon restoration of the 
euthyroid state.  
The observed changes of hepato-biliary- and 
cellular function could be explained by 
reversible non alcoholic hepatic steatosis 
(NASH) occurring in mild thyroid failure. 
However, hepatocellular tissue in primary 
thyroid failure has never been investigated. 
Structural changes of the hepatocyte with 
intracellular fat deposition could potentially 
explain the distinct findings in hepato-biliary 
and hepato-cellular function in our study.  
Our study has some limitations. Circulating 
ALP levels originate not only from the liver 
but also from bone. However, we calculated 
the concentration of liver specific ALP level 
by subtracting the B-ALP level from total 
ALP. B-ALP did not change significantly after 
48 weeks of L-T4 therapy. Accordingly, 
results for serum liver-specific ALP levels 
were comparable to circulating total ALP 
concentrations (data not shown). Since serum 
ALP and other changes remained in the 
normal reference range throughout the study 
period, the clinical relevance of our findings 
could be questioned. However, normal 
reference ranges are a measure of inter-
individual variance and the ‘normal range’ for 
a specific individual is much less wide. 
Accordingly, individual changes observed in 
this double blind study can be relevant for an 
affected patient, despite being within the so-
called ‘normal range’. One might also argue 
that the TSH levels at the end of the study 
were still in the high-normal range in L-T4 
treated patients indicating that some patients 
were metabolically still hypothyroid. Indeed, 
of the 31 L-T4 treated patients 7 had a TSH 
level above 4mU/L and 3 above 5mU/L. 
Hence, further lowering of TSH levels could 
have even increased the impact on lipid profile 
and changes of hepato-biliary function.  
In conclusion, thyroid hormone replacement 
affects biliary function in patients with SCH, 
leading to mildly increased hepato-biliary 
enzymes. In contrast, L-T4 treatment overall 
has no significant effect on markers of 
hepatocellular-function. However, 
improvement in LDL-C levels in SCH is 
significantly associated with changes of AST 
and ALT, compatible with changes of hepatic 
lipoprotein catabolism and a restored hepato-
cellular function. 
 
 9
REFERENCES 
 
Azizi F. Gamma-Glutamyl transpeptidase levels in 
thyroid disease. Arch Intern Med 1982;142:79-81 
 
Burnett JR, Crooke MJ, Delahunt JW, Feek CM. Serum 
enzymes in hypothyroidism. New Zealand Medical 
Journal 1994;107:355-6 
 
Cooper DS. Clinical practice. Subclinical 
hypothyroidism. N Engl J Med 2001;345:260-5 
 
Danese MD, Ladenson PW, Meinert CL, Powe NR. 
Clinical review 115: effect of thyroxine therapy on 
serum lipoproteins in patients with mild thyroid failure: 
a quantitative review of the literature. J Clin Endocrinol 
Metab 2000;85:2993-3001 
 
Fagiuoli S, Van Thiel DH. The liver in 
endocrine disorders. Raven Press 1993, New York, NY 
 
Gartner LM, Arias IM. Hormonal control of hepatic 
bilirubin transport and conjugation. Am J Physiol 
1972;222:1091-9 
 
Gow SM, Caldwell G, Toft AD, Beckett GJ. Different 
hepatic responses to thyroxine replacement in 
spontaneous and 131I-induced primary hypothyroidism. 
Clin Endocrinol (Oxf) 1989;30:505-12 
 
Klion FM, Segal R, Schaffner F. The effect of altered 
thyroid function on the ultrastructure of the human liver. 
Am J Med 1971;50:317-24 
 
Layden TJ, Boyer JL. The effect of thyroid hormone on 
bile salt-independent bile flow and Na+, K+ -ATPase 
activity in liver plasma membranes enriched in bile 
canaliculi. J Clin Invest 1976;57:1009-18 
 
Meier C, Staub JJ, Roth CB, et al. TSH-controlled L-
thyroxine therapy reduces cholesterol levels and clinical 
symptoms in subclinical hypothyroidism: a double 
blind, placebo-controlled trial (Basel Thyroid Study). J 
Clin Endocrinol Metab 2001;86:4860-6 
 
Muller MJ, Beke KHW, Selberg O. Are patients 
with liver cirrhosis hypermetabolic ? Clin Nutr 
1994;13:131-44 
 
O'Brien T, Katz K, Hodge D, Nguyen TT, Kottke BA, 
Hay ID. The effect of the treatment of hypothyroidism 
and hyperthyroidism on plasma lipids and 
apolipoproteins AI, AII and E. Clin Endocrinol (Oxf) 
1997;46:17-20 
 
Packard CJ, Shepherd J, Lindsay GM, Gaw A, Taskinen 
MR. Thyroid replacement therapy and its influence on 
postheparin plasma lipases and apolipoprotein-B 
metabolism in hypothyroidism. J Clin Endocrinol 
Metab 1993;76:1209-16 
 
Salter AM, Hayashi R, Al-Seeni M, et al. Effects of 
hypothyroidism and high-fat feeding on mRNA 
concentrations for the low-density-lipoprotein receptor 
and on acyl-CoA:cholesterol acyltransferase activities in 
rat liver. Biochemical Journal 1991;276:825-32 
 
Tajiri J, Shimada T, Naomi S, Umeda T, Sato T. 
Hepatic dysfunction in primary hypothyroidism. 
Endocrinol Jpn 1984;31:83-91 
 
Tan KC, Shiu SW, Kung AW. Effect of thyroid 
dysfunction on high-density lipoprotein subfraction 
metabolism: roles of hepatic lipase and cholesteryl ester 
transfer protein. J Clin Endocrinol Metab 
1998;83:2921-4 
 
Thompson P, Jr., Strum D, Boehm T, Wartofsky L. 
Abnormalities of liver function tests in tyrotoxicosis. 
Mil Med 1978;143:548-51 
 
Van Steenbergen W, Fevery J, De Vos R, Leyten R, 
Heirwegh KP, De Groote J. Thyroid hormones and the 
hepatic handling of bilirubin. I. Effects of 
hypothyroidism and hyperthyroidism on the hepatic 
transport of bilirubin mono- and diconjugates in the 
Wistar rat. Hepatology 1989;9:314-21 
 
Vergani C, Trovato G, Delu A, Pietrogrande M, 
Dioguardi N. Serum total lipids, lipoprotein cholesterol, 
and apolipoprotein A in acute viral hepatitis and chronic 
liver disease. J Clin Pathol 1978;31:772-8 
 
